Because of the high cost and long time frame of clinical testing, animal models play a crucial role in the identification and selection of agents for the treatment of osteoporosis. The use of animal models early in a program focuses on the establishment of efficacy, while animal models used later in a program to examine bone safety. More specifically, animal models are used to gain information on the skeletal mechanism of action, to examine multiple skeletal sites (axial and appendicular), and to examine the effects of higher doses than will be used in humans. Animal models also predict the usefulness of surrogate markers in clinical trials, such as formation and resorption markers, as well as bone density. The hazard of using surrogate markers for fracture prevention is highlighted by high dose fluoride administration, which can increase bone density (considered a strong predictor of fracture protection) while not protecting against fractures. Estrogen-deficient models are most commonly used to mimic the postmenopausal bone loss in women; these models are characterized by increased bone turnover and a negative bone balance. The timing of the administration of the new therapy in animal models can help determine whether the agent will be more effective in the prevention of osteoporosis or in the treatment of established osteoporosis. New methods for the measurement of bone mass or volume are less invasive, require shorter acquisition time, and have enhanced resolution, resulting in increased knowledge concerning architectural changes and specific sites of bone deposition. Finally, the measurement of biomechanical strength of bones from animal models can be used to predict protective effects on fracture rates in clinical trials. When used in combination with other methods, animal models can greatly increase our understanding of the pathophysiology of osteoporosis and can expedite the development of new therapies.
rently, the disease prevalence of postmenopausal osteoporosis is estimated at 10-12 million women worldwide (29, 41) . The incidence of osteoporosis is increasing with the extended average life span of the world population (28) . Significant morbidity and mortality is associated with spinal, hip, and wrist fractures. Risk factors for excessive bone loss include low levels of physical activity, poor nutritional habits, and estrogen deficiency (41) .
Bone mass in humans peaks around the third decade in life, and then declines slowly with age. Bone loss in women is temporarily accelerated during and after the menopause as a consequence of estrogen deficiency (13, 14, 27, 29, 41) . Osteoporosis in men is less common, most likely because of a higher peak bone mass. Corticosteroid administration can also be associated with a significant loss of bone mass and development of osteoporosis at any age.
BONE PHYSIOLOGY
The aging process in humans is associated with a slow loss of bone mass. This loss of bone is the lifelong accumulation of a slight deficit in replacement of bone dur-ing each remodeling cycle (9) . The remodeling cycle of bone consists of osteoclast activation, osteoclast resorption and pit formation, osteoblast recruitment, and osteoblastic bone formation. In the development of osteoporosis, each osteoclast resorption pit is not quite completely filled in by new bone. The slight loss of bone with each remodeling cycle is called a negative bone balance. Whether the defect is in slightly overactive osteoclasts with resorption of a pit that is too deep or underactive osteoblasts that do not form enough bone to fill in the pit is not clear. With each remodeling cycle, a little more bone is lost, until the skeleton becomes fragile. A negative bone balance is the basic defect in osteoporosis. The net result is both a loss of bone mass and a loss of trabeculae, which occurs when an osteoclast completely perforates through a trabecula and destroys the template for osteoblastic bone formation (20, 34) .
Normally, bone remodeling occupies a small percentage of the skeletal mass at any time point. The amount of the bone mass that undergoes remodeling during a fixed period of time is defined as the turnover rate. Turnover rate is increased by estrogen deficiency (1, 14, 29) . This increased turnover rate temporarily increases bone loss because the same small amount of bone is lost with each repetition of the remodeling cycle. Estrogen deficiency therefore, temporarily accentuates the negative bone balance seen with aging and accelerates the loss of bone.
The long-term cure for osteoporosis is the development of a positive bone balance with each remodeling cycle, resulting in a sustained increase in total bone mass and a skeleton that no longer fractures with minimal forces. Current therapies for osteoporosis are aimed at reducing resorption activity and the turnover rate, which therefore reduces the net bone loss. Although bone mass (as measured by densitometry) increases with antiresorptive therapy and fracture rates are reduced, fracture occurrence is still not zero. New therapies that address the basic deficit in osteoporosis, i.e., the negative bone balance with each remodeling cycle, are needed.
PRECLINICAL PROGRAM
The initial goal of preclinical studies is the establishment of efficacy, which then provides justification for the further progression of compounds into clinical testing. Efficacy is especially important to establish in osteoporosis therapy because of the long-term nature of trials and the substantial investment of resources. After a compound has shown sufficient merit to progress into clinical trials, the emphasis on preclinical bone studies shifts to the establishment of long-term bone safety. Therapeutic efficacy for osteoporosis prevention or treatment will be established in humans as a reduction in fracture incidence (10, 35) . Preclinical models are also used to establish nontarget organ safety.
PRECLINICAL EFFICACY
Several models have provided reliable predictions in the search for therapeutic agents for the treatment of osteoporosis (11, 32) . The most commonly used model for osteoporosis is the ovariectomized (OVX) rat model because of its small size, rapid bone loss with estrogen deficiency, and availability (1, 51) . Because the acceleration of bone turnover caused by estrogen deficiency at menopause is the most common cause of osteoporosis, animal models that lose bone in response to estrogen deficiency are preferred in the preclinical examination of therapeutic agents. This bone loss should be characterized by an increased turnover rate, decreased bone mass as measured by densitometry, and decreased bone volume as measured by histomorphometry (21) . Significant changes in architecture characterized by dropout of trabeculae should also be seen in the models (20, 34) .
Early preclinical efficacy testing is carried out in abbreviated models. Young animals are utilized because they are more readily available and the disease onset can be accelerated by surgical induction of estrogen deficiency (48, 49) . Animal models do not exhibit some features of the human disease, such as skeletal fragility or spontaneous fractures. Biomechanical measurements of excised bones are used as a surrogate for fracture incidence rates. However, the high variability of these measures and the differences in anatomy (both hip and vertebra) limit the utility of these measures in animal models. For example, vertebrae from animals have a significantly thicker cortical shell than does the human vertebra. The contribution of this cortical shell to the measurement of the maximum load prior to fracture may mask positive or negative changes in the cancellous bone of the vertebra, which is the primary envelope for strengthening the human vertebra. Similar difficulties are present when measuring the biomechanical strength of the femoral neck, where there are differences in the amount of cortical and cancellous bone and overall geometry, such as the length of the neck.
Preclinical models are also used to confirm the utility of clinical measurements (such as densitometry and systemic bone metabolism markers) and to examine in detail the effects of the therapy at multiple locations in the skeleton (35) . The increase in bone mass in the preclinical model should be correlated with a commensurate increase in bone strength. The concern that increases in bone density or volume may not directly predict fracture resistance is supported by data from studies of high-dose fluoride, which increased bone mass in humans but also increased the vertebral fracture rate (40) . These data have had a significant impact on the design of preclinical and clinical programs for osteoporosis therapy, resulting in greater reliance on bone strength (in animal models) or fracture incidence (in humans) as end points. For these reasons, preclinical models that have increased dose levels and comparable length of dosing (when normalized for skeletal turnover time) are utilized to provide additional information on bone efficacy and safety. The concerns that bone mass measurements may not always predict fracture resistance and that anatomical differences exist among animal models have increased the reliance on reduction in fracture frequency in osteoporotic humans as the efficacy end point for new osteoporosis therapies.
PRECLINICAL SAFETY
Preclinical models are used to detect any deleterious effects on mineralization, matrix quality, or architecture (35) . Long-term exposure to any agent that changes the bone remodeling rate or matrix deposition has the potential to result in poor bone quality (impairment of growth, mineralization defects, reductions in bone mass, and skeletal fragility) (40) . Preclinical models are also used to understand how agents affect bone physiology, whether they decrease levels of bone resorption or increase levels of bone formation (11, 21, 24) . This information can be used to predict long-term benefits or consequences of therapy. The Food and Drug Administration has released draft guidelines for the approval of agents for the prevention or treatment of postmenopausal osteoporosis (10) . These ) the studies should include a modeling species (rat) and 1 remodeling species. The stipulation for 5 times the clinical dose is necessary to assess any untoward effects that may occur in humans with long-term dosing or increased bioavailability (40, 43) . These preclinical studies are designed to support the safety aspects of the therapy, i.e., to confirm that the bone mass increase is commensurate with an increase in bone strength.
ANIMAL MODELS
Although animal models of osteoporosis do not exhibit all the characteristics of the human disease, such as skeletal fragility, many characteristics are similar, and thus these models provide excellent opportunities to mimic specific aspects of the human disease (33, 35) . Some of the key components of animal models of postmenopausal osteoporosis have been used to develop several clinical therapies such as estrogens, bisphosphonates, and calcitonin. The most common method used to induce bone loss in animal models is estrogen deficiency through ovariectomy. Estrogen deficiency bone loss is characterized by increased bone turnover rate, bone loss from both cancellous and cortical envelopes, loss of trabeculae through perforation, and endosteal resorption with expanded marrow area (for reviews, see 11, 32) .
Rat
The ovariectomized Sprague-Dawley rat is commonly used to model postmenopausal osteoporosis because there is a rapid and reproducible bone loss in response to estrogen deficiency (33, 48, 49, 50, 51, 53) . Mechanical strain also modulates bone balance in rats (47) . As a model, however, the rat has 2 major drawbacks: (a) rats grow continuously throughout life (the growth plates do not completely close), and (b) rats do not remodel their cortical bone (11) and therefore may not provide accurate predictions of the cortical bone effects of new therapies. Also, the absolute thickness of rat trabecular bone is smaller than that of other large animals, and the architectural changes in rats may not reflect changes that occur in larger species (1, 24) . Nevertheless, the ovariectomized rat model has shown a strong predictive ability for osteoporosis therapeutic agents. Results from this model should be interpreted with the knowledge of the mechanism of action of the new therapy and the etiology of postmenopausal osteoporosis.
Dog
The dog skeleton has a remodeling physiology that is similar to that of humans, both in terms of remodeling cycle time and the histomorphometry of the remodeling units. The dogs also has cortical haversian remodeling similar to that of humans (25, 42) . However, the dog does not have a sustained loss of bone mass in response to estrogen deficiency caused by ovariectomy. The only consistent skeletal change in response to estrogen deficiency in the dog has been an increase in bone turnover rate, as seen by histomorphometry as an increase in mineralizing and resorption surface (2, 6) . Because of the lack of a permanent decrease in bone volume in response to ovarian hormone deficiency, most experiments utilize intact dogs.
Mini-pig
The size of the mini-pig, the histomorphometric similarities of the porcine skeleton to human bone, and the monogastric intestinal physiology of the pig are advantages of this model (44) . The ovariectomized mini-pig also shows many features of postmenopausal osteoporosis, including a significant loss of bone mass due to es-trogen deficiency, especially in conjunction with mild calcium restriction (6-10% in the lumbar vertebra by dual energy x-ray absorptiometry [DXA] ) (36, 37) . The minipig model also demonstrates a loss of trabeculae, with decreased trabecular connectivity and endosteal bone resorption by histomorphometry (37) . Studies primarily have utilized young adults shortly after closure of the growth plates. However, skeletal maturation that occurs after growth plate closure is seen as an increase in bone mineral density and can complicate the measurement of bone effects.
Sheep
The availability of aged animals is unique to the sheep model of postmenopausal osteoporosis. Surgical induction of estrogen deficiency in the aged sheep produces a loss of bone mass and increased bone turnover, as measured by bone markers (18, 38, 45, 46) . This model is also useful for the study of additional effects of aging on the skeleton, including loss of dentition. Complications can arise from the fact that sheep are seasonal breeders and the corresponding physiologic decrease in estrogen for the noncycling months can mimic surgical estrogen deficiency in the sham-ovariectomized animals. Estrogen supplementation of the sham animals can be used to avoid physiologic estrogen depletion due the seasonal estrous cycles characteristic of the sheep (46) . One drawback of this model is the ruminant gastrointestinal physiology if an agent is administered by the oral route.
Nonhuman Primate
The physiologic similarities of nonhuman primates to humans and the occurrence of natural menopause in some primates are advantages of this model (19, 21-23, 26, 31, 39) . However, the loss of bone mass in response to ovariectomy is variable, perhaps because of changes in care and diet in animals caught from the wild, skeletal maturation after growth plate closure, or differences in skeletal loading and physiology. Most studies do demonstrate significant differences between intact and ovariectomized animals, although in some cases the difference is generated through an increase in bone mass in the intact animals as well as a slight decline in the ovariectomized animals. The availability of aged animals and the cost of nonhuman primates can limit the use of this model.
Additional Osteoporosis Models
Although less commonly utilized, immobilization (disuse) or corticosteroid administration can induce osteoporosis in animals. Microgravity and microgravity models (bed rest or tail-suspended rat models) also produce a significant decrease in bone mass (16, 52) . The use of these models is limited by the desire to investigate therapies for the most common cause of osteoporosis, which is postmenopausal estrogen deficiency (15) . MEASUREMENT 
TECHNIQUES

Markers of Bone Turnover
The noninvasive estimation of bone turnover through serum and urinary markers is a recent development and will likely be used in all clinical studies, both to support initial efficacy and to determine the mechanism of action of proposed therapeutic agents (8) . Bone markers offer a significant advantage over biopsies or densitometry in that they assess the effects of therapy on the entire skeleton rather than a single site (3, 12, 13) . The noninvasive nature of bone markers also allows repeated measures of the same individual. Formation markers include bonespecific alkaline phosphatase, osteocalcin, and type 1 procollagen peptide. These markers have shown close correlation with histomorphometry and the age/growth rate of patients. However, these formation markers can be affected by diseases states, such as renal or liver failure (due to slow degradation), and demonstrate significant circadian rhythms (3, 7, 12) . Resorption markers include urinary hydroxyproline, pyridinoline and deoxypyridinoline cross-links, and cross-linked N-telopeptides. These compounds represent degradation products of collagen that can be measured in urine or, more recently, in serum (3) . Markers work well for the monitoring of clinical efficacy and prediction of fractures (8, 12) . In animal models, these markers are used to measure efficacy and to validate their use in human studies.
Densitometry Techniques
Densitometry is widely utilized in the clinical diagnosis of osteoporosis and for monitoring therapy (17, 27, 30) . Densitometry is the quantification of the x-ray attenuation by bone and is used to estimate the amount or the structure of the skeleton. Dual energy x-ray absorptiometry (DXA) is the most commonly used clinical measurement for the diagnosis of osteoporosis. DXA uses the differential absorption of two x-ray beams (at different energy levels) to quantify the skeletal mass. The lowenergy beam is used to correct the measurement for the absorption of x-rays by the soft tissue. This method produces a rapid 2-dimensional representation of bone mass but provides minimal information on bone architecture.
In contrast to DXA, computed tomography can be used to produce a 3-dimensional measure of bone mass. Tomography uses multiple views from different angles of the same slice of bone, and computer algorithms are used to reconstruct the bone architecture. These techniques provide more detail but are more time consuming, and therefore they are less widely used for the measurement of bone mass. Computed tomography can be used to quantify the bone mass in specific compartments such as the cortical or cancellous regions and directly measure the effects of therapy in specific regions (4) . Computed tomography can also use beam magnification at a resolution high enough to allow evaluation of an individual trabecula. These data can then be used for a detailed study of the 3-dimensional architecture of a bone, including the orientation of trabeculae, the connectivity of trabeculae, and the prediction of strength for cancellous bone.
Histomorphometry
Histomorphometry is the classical technique used to measure the efficacy of bone therapy (9) . Sections of undecalcified bone are used to measure the total bone volume from a 2-dimensional slice. The incorporation of fluorescent labels administered at intervals during the study can produce a snapshot of formation rates at specific time points during a study, providing data on turnover rate and mechanism of action of new bone therapies (53) . SUMMARY Preclinical evaluation of agents for the treatment of osteoporosis gives information on the skeletal mechanism of action, the long-term skeletal safety, and bone efficacy at multiple sites. The concern that bone mass increases may not always predict increased fracture resistance has resulted in the reliance on fracture reduction in osteoporotic humans as the efficacy end point for new osteoporosis therapies. Although this end point certainly increases confidence in the efficacy of new drugs, it also greatly increases the cost and time of development of new therapies. Preclinical models can help minimize the risk in developing new osteoporosis therapies by using them as predictors of the outcome of human fracture trials. Preclinical models also provide additional information to assure the safety of new osteoporosis therapies.
